EA201490552A1 - Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью - Google Patents

Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью

Info

Publication number
EA201490552A1
EA201490552A1 EA201490552A EA201490552A EA201490552A1 EA 201490552 A1 EA201490552 A1 EA 201490552A1 EA 201490552 A EA201490552 A EA 201490552A EA 201490552 A EA201490552 A EA 201490552A EA 201490552 A1 EA201490552 A1 EA 201490552A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclobutendion
cholino
aninfestive
owned
substituted
Prior art date
Application number
EA201490552A
Other languages
English (en)
Inventor
Амит Виджай Амбаркхане
Арно Моле
Карстен Тимпе
Урс Беттиг
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201490552A1 publication Critical patent/EA201490552A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Abstract

6-Хлор-3-[2-(1-этилпропиламино)-3,4-диоксоциклобут-1-ениламино]-2-гидрокси-N-метокси-N-метилбензолсульфонамида холин, твердые фармацевтические композиции и пероральные дозированные формы, которые содержат указанное соединение, и способ применения таких композиций и пероральных дозированных форм для лечения человека, который страдает от воспалительных, обструктивных или аллергических патологических состояний и заболеваний.
EA201490552A 2011-09-02 2012-08-31 Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью EA201490552A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02
PCT/IB2012/054502 WO2013030803A1 (en) 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound

Publications (1)

Publication Number Publication Date
EA201490552A1 true EA201490552A1 (ru) 2014-11-28

Family

ID=47116123

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490552A EA201490552A1 (ru) 2011-09-02 2012-08-31 Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью

Country Status (17)

Country Link
US (1) US9018261B2 (ru)
EP (2) EP2760821B1 (ru)
JP (3) JP2014529621A (ru)
KR (1) KR102024955B1 (ru)
CN (1) CN103842330B (ru)
BR (1) BR112014004963A2 (ru)
CA (1) CA2846510C (ru)
EA (1) EA201490552A1 (ru)
ES (1) ES2655942T3 (ru)
HU (1) HUE035751T2 (ru)
IN (1) IN2014DN02346A (ru)
MX (1) MX359259B (ru)
NO (1) NO2679622T3 (ru)
PL (1) PL2760821T3 (ru)
PT (1) PT2760821T (ru)
SI (1) SI2760821T1 (ru)
WO (1) WO2013030803A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
EP3737366A4 (en) 2018-01-08 2022-07-27 ChemoCentryx, Inc. METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3124935A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
NZ294762A (en) 1994-11-16 1998-11-25 American Home Prod Diaminocyclobutene-3,4-dione derivatives, preparation and pharmaceutical compositions thereof
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EP1358160A1 (en) 2001-02-07 2003-11-05 Abbott Laboratories Aminal diones as potassium channel openers
BR0208510A (pt) 2001-03-30 2005-04-19 Smithkline Beecham Corporatiio Métodos de sìntese de compostos contendo fenol
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
SI1818325T1 (sl) 2001-04-16 2010-06-30 Schering Corp DI substituirani ciklobuten dioni kot ligandi CXC kemokinskega receptorja
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
AU2005210504B2 (en) 2004-01-30 2009-01-08 Merck Sharp & Dohme Corp. Crystalline polymorphs of a CXC-chemokine receptor ligand
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
KR20070104460A (ko) 2005-02-10 2007-10-25 와커 헤미 아게 보호된 이소시아네이트기를 가지는 입자를 함유하는 래커
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
BRPI0713559A2 (pt) 2006-07-07 2012-03-13 Schering Corporation Composto ciclobuteno-1,2-dionas 3,4-di-substituídas, composição farmacêutica compreendendo o mesmo e usos do mesmo
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
WO2008109178A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a squaramide moiety
ES2386489T3 (es) 2007-06-06 2012-08-21 Novartis Ag Compuestos ciclobutanediona sustituidos anti-inflamatorios
WO2009005801A1 (en) 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
JP2010532357A (ja) 2007-07-05 2010-10-07 シェーリング コーポレイション １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
EP2252327A2 (en) 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US8404725B2 (en) 2008-08-04 2013-03-26 Merck Patent Gmbh Phenylamino isonicotinamide compounds
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
TW201022253A (en) * 2008-11-14 2010-06-16 Portola Pharm Inc Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Also Published As

Publication number Publication date
PT2760821T (pt) 2018-01-11
HUE035751T2 (hu) 2018-08-28
BR112014004963A2 (pt) 2017-03-21
PL2760821T3 (pl) 2018-04-30
CA2846510A1 (en) 2013-03-07
JP6612200B2 (ja) 2019-11-27
CN103842330A (zh) 2014-06-04
NO2679622T3 (ru) 2018-01-20
KR20140059264A (ko) 2014-05-15
IN2014DN02346A (ru) 2015-05-15
MX359259B (es) 2018-09-20
US9018261B2 (en) 2015-04-28
JP2017025081A (ja) 2017-02-02
CA2846510C (en) 2019-10-22
EP3287438A1 (en) 2018-02-28
KR102024955B1 (ko) 2019-09-24
ES2655942T3 (es) 2018-02-22
US20140206768A1 (en) 2014-07-24
JP2019001787A (ja) 2019-01-10
EP2760821B1 (en) 2017-10-11
JP2014529621A (ja) 2014-11-13
CN103842330B (zh) 2016-10-19
WO2013030803A1 (en) 2013-03-07
EP2760821A1 (en) 2014-08-06
SI2760821T1 (en) 2018-02-28
MX2014002492A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201290919A1 (ru) Индазольные соединения и их применение
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201690962A1 (ru) Составы
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена